Introduction
Methionine adenosyltransferase (MAT) deficiency (OMIM # 250850) was first described by Gaull and Tallan in 1974 in an infant with hypermethioninemia, 1 who had normal development on follow-up. 2 Many subsequent reports described that patients with hypermethioninemia correlated to MAT deficiency based on decreased activity of the enzyme in liver biopsy. The key factor to identify most of the reported cases in the literature was the implementation of the newborn screening program to discover hypermethioninemia due to cystathionine beta-synthase deficiency. 3 The molecular basis of the disease was established for the first time by Ubagai et al. 4 Further delineation of the MAT1A mutations and the mode of inheritance were elaborated by Chamberlin et al. 5 Clinically, although the majority of patients are asymptomatic, some might have central nervous system (CNS) manifestations. 5 Additionally, patients may have extra-CNS manifestations like malodorous breathing. 6, 7 Biochemical findings include plasma hypermethioninemia ranging from mild elevation to .2,000 µM. Patients usually have decreased or complete loss of MAT I/III activity resulting in low S-adenosyl methionine (AdoMet) level. Furthermore, some patients were reported to have mild elevation in homocysteine level. 
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Nashabat et al MAT deficiency is inherited either as autosomal recessive or autosomal dominant. MAT1A mutations described previously range from truncating mutations with no residual enzyme activity to mild missense mutations. 8 There is no consensus, with a high level of evidence, regarding recommended management plan in the literature. 8 Many inputs should be considered like confirmation of the diagnosis, plasma methionine level, and CNS involvement, before starting treatment. The most commonly used treatment modalities are methionine restriction diet and AdoMet supplementation. 3, [8] [9] [10] The most recent recommendations for the diagnosis and management of all inherited methylation disorders were reviewed by Baric et al. 11 In this report, we describe the first case in the literature of MAT deficiency in Saudi Arabia with novel mutation not described previously, in addition to a unique presentation with skin features of acrodermatitis enteropathica with severe zinc deficiency necessitating oral supplementation.
Case report
A 40-month-old male patient, who was a product of spontaneous vaginal delivery after full-term uneventful pregnancy to a healthy 32-year-old woman and her 34-year-old first cousin. Birth weight was 3.28 kg, length at 50 cm, and head circumference at 34.5 cm, all were around the median, with APGAR scores of 9 and 9 at 5 and 10 minutes, respectively. The patient underwent newborn screening tests as part of the routine care for all newborns, which showed elevated methionine at 105 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) µmol/L. A repeated sample confirmed the elevation at 85 µmol/L. Clinically the patient was stable with unremarkable complete systemic examination.
Other metabolic investigations were requested including homocysteine, and urine for organic acids and methylmalonic acid but all were unremarkable. Renal and liver functions were unremarkable.
At the age of 2 months, the patient developed irritability and skin eruption consisting of multiple scaly and erosive hyperkeratotic plaques all over the body but most pronounced on lower extremities. In addition to leukotrichia and positive hair pull test (Figure 1 ), his zinc level was very low at 3.4 (9.18-18.36) µmol/L. All skin eruptions started to resolve after oral zinc supplementation over 2 weeks (Figure 1 ).
At the age of 6 months, the final diagnosis was reached by the genetic study of MAT1A (NM_000429.2), which revealed a homozygous variant in c.1081G.T (p.Val361Phe). In silico study predictions were as follows: Mutation taster 
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MAT I/III deficiency: beyond the CNS manifestations mutation was negative. All the genetic tests requested for the patient were single gene sequencing done at commercial accredited labs.
In addition, the patient was found to have iron deficiency, which was discovered at 9 months of age; hemoglobin level was 90 (110-145) g/L, mean corpuscular volume (MCV) 62.4 (75-89) fL, mean corpuscular hemoglobin (MCH) 17 (25) (26) (27) (28) (29) (30) pg, serum iron 4.8 (9-21.5) µmol/L, and ferritin 7 (21.8-274.6) µg/L. Consequently, ferrous sulfate was prescribed.
Of note, the patient's nutritional history was unremarkable during the time he developed the symptoms. He had combined breast and formula feeding initially then he was receiving regular diet. His feeding was well and he had acceptable feeding habits. The family history was negative for MAT, zinc, or iron deficiency.
Currently, the patient is 40 months old with normal developmental milestones except for mild speech delay in the form of dysarthria. All his growth parameters are around the median. He is still on zinc and iron supplementation. All the skin and hair symptoms improved. The patient's zinc level is still low at 6.79 (9.18-18.36) µmol/L. The serum ferritin is still low at 13.7 (21.8-274.6) µg/L, hemoglobin was normalized at 128 g/L, while MCV and MCH are slightly low at 71.1 (75-89) fL and 24.2 (25-30) pg, respectively. Latest lab investigations showed methionine at 34 µmol/L and homocysteine at 6.1 (#15) µmol/L. The highest methionine reading reported for our patient was 110 µmol/L and the average was at 59.2 µmol/L.
Discussion
MAT1A encodes the two MAT isozymes I and III. 4 MAT acts predominantly in liver but also present in other tissues. 15, 16 MAT catalyzes the first step in the methionine cycle to synthesize AdoMet. 17 MAT deficiency results in variable ranges of hypermethioninemia and decreased AdoMet level, based on the type of gene mutation. Although truncating mutations are thought to cause a severe phenotype with high methionine level and neurologic derangement, this was not true in all cases. Some of the patients harbor truncating mutations and had a markedly elevated methionine level, but still they developed normally. 4, 8 In our patient, although the methionine level was mildly elevated, he had signs of developmental delay.
MAT deficiency is inherited either as autosomal-dominantor autosomal-recessive trait like our patient. Initially, it was thought that the autosomal recessive is the most common way of inheritance, but after the implementation of newborn screening, more heterozygous mild cases were discovered. This set the fact that the autosomal-dominant inherited genotype is the most common. 8 Our patient had a novel homozygous mutation c.1081G.T (p.Val361Phe) in MAT1A gene that was not reported before.
Additionally, our patient had unexplained zinc deficiency with temporary features of acrodermatitis enteropathica. This may raise the suspicion of impaired zinc absorption. Bauchart-Thevret et al studied the effect of dietary sulfur amino acids deficiency on neonatal pigs and concluded that it results in suppression of the epithelial growth, which was manifested as villous atrophy and caused upregulation of the methionine cycle in the intestine. 18 Villous atrophy is a well-known cause of zinc and iron deficiency in many gastrointestinal diseases. [19] [20] [21] However, our patient did not have clinical symptoms of villus atrophy.
Zinc deficiency could be due to a wide spectrum of causes, usually categorized in either decreased intake, malabsorption, increased loss, or increased demand. 22 None of these categories fit our patient, and accordingly, we tried to investigate for the other genetic causes including SLC39A, which was negative.
A long list of causes can result in iron deficiency, among which are the four categories mentioned above. Our patient was completely symptomatic, with balanced diet, no signs of malabsorption, and no signs of increased loss and even no increase in the demand. 23 Although the cause of iron and zinc deficiency in our patient is still obscure, it is not clear whether they could be correlated with MAT1A mutation or not.
Neurologic manifestations and demyelination have been correlated to MAT deficiency in many reported cases. 24, 25 But none of the previous reports shed light on extra-CNS manifestations associated with the disease. Table 1 summarizes all the previously reported cases with extra-CNS manifestations.
By reviewing all the reported cases in the literature, we found that many extra-CNS manifestations were reported sporadically along with MAT deficiency. Some of these signs and symptoms could be explained by the pathophysiology of the disease like the malodorous mouth breath and the boiledcabbage odor. 6 On the other hand, the remaining manifestations were not completely explained. The pathophysiology of the MAT deficiency is centered around two themes: elevated methionine level and deprived AdoMet level. 26 AdoMet is involved in tremendous cellular functions, 16 which, in theory, might have variable clinical consequences.
Gout et al reported anorexia, digestive disturbances, and growth retardation in their case, in addition to the CNS manifestations. 27 Subsequent reports mentioning the same submit your manuscript | www.dovepress.com
Dovepress
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Nashabat et al patient did not comment on any of these symptoms. Instead, they reported a normal cognitive function, 5,28 which could be a clue of improvement. Similarly, our patient's skin and hair symptoms improved with time.
Martins et al reported vasculopathy in three families with MAT deficiency, which was correlated to the elevated total homocysteine as a possible risk factor for vasculopathy. 29, 30 Although elevated total homocysteine was reported in many other cases of MAT deficiency, vasculopathy was not mentioned in any of them. 10, [31] [32] [33] Among all the reported MAT deficiency cases, only one patient was reported to have unexplained moderate hepatomegaly. 31 None of the other reported cases, including our patient, had a liver injury or developed hepatocellular carcinoma, which is against that observed in MAT1A knocked-out mice models. 34, 35 To conclude, MAT deficiency patients should be thoroughly investigated to check for CNS and extra-CNS manifestations associated with the disease. It is still not easy to correlate the genotype and phenotype of this disease. A scrutinized look at the extra-CNS manifestations and their course might pave the way to better understand the pathophysiology of the disease and MAT1A function. 37 Hazelwood et al, 25 Chamberlin et al 24 Yes stabler et al, 26 Linnebank et al, 31 Couce et al, 32 Couce et al 
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